Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 2Cholangiocarcinoma 2Carcinoma, Intraductal, Noninfiltrating 2Sarcoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lymphedema 1Lymphatic Metastasis 1Lung Neoplasms 1Glioblastoma 1Gallbladder Neoplasms 1Endometrial Neoplasms 1Encopresis 1Carcinoma, Non-Small-Cell Lung 1Breast Carcinoma In Situ 1Breast Cancer Female 1

Interventions

pembrolizumab 34Specimen Handling 18Paclitaxel 16Magnetic Resonance Spectroscopy 15Carboplatin 14Biopsy 14Nivolumab 13Ipilimumab 12Gemcitabine 10Irinotecan 9Radiosurgery 8atezolizumab 7abemaciclib 7Radiation 7Pemetrexed 7Cisplatin 7Capecitabine 7130-nm albumin-bound paclitaxel 7trastuzumab deruxtecan 6olaparib 6durvalumab 6avelumab 6Docetaxel 6osimertinib 5adagrasib 5Trastuzumab 5Fulvestrant 5Cetuximab 5Albumin-Bound Paclitaxel 5palbociclib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasm Metastasis × Radiation Dose Hypofractionation × Clear all
NCT04068194 2026-05-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
103 enrolled
Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡